INTRODUCTION {#S2}
============

As the most abundant mRNA modification, *N*^6^-methyladenosine (m^6^A) modification is reversible and plays critical roles in multiple fundamental biological processes (e.g., cell differentiation, tissue development, and tumorigenesis)^[@R1]--[@R13]^. High throughput sequencing revealed that m^6^A is especially enriched in the 3′ untranslated regions (UTRs) and near the stop codons of mRNAs with a consensus sequence of RRACH (R=G or A; H=A, C or U)^[@R2],\ [@R3]^. The biological importance of m^6^A modification relies on m^6^A-binding proteins (i.e., readers). Therefore, it is crucial to identify and characterize m^6^A readers that directly guide distinct bioprocesses. A group of YT521-B homology (YTH) domain-containing proteins have been identified as m^6^A readers that control messenger RNA (mRNA) fate by regulating pre-mRNA splicing, facilitating translation, or promoting mRNA decay^[@R2],\ [@R10],\ [@R14]--[@R16]^.

In the YTHDF2-mediated decay pathway^[@R10]^, mRNA levels are expected to increase when m^6^A abundance is reduced. However, our recent data showed that a large portion of mRNAs with reduced m^6^A abundance tended to be down-regulated due to decreased RNA stability^[@R12]^, suggesting the presence of alternative mechanism(s) to stabilize m^6^A-modified mRNAs. Here we report the insulin-like growth factor-2 (IGF2) mRNA-binding proteins 1, 2, and 3 (IGF2BP1/2/3) as a new family of m^6^A readers that guard m^6^A-modified mRNAs from decay. IGF2BPs, a conserved family of single-stranded RNA-binding proteins^[@R17]^, are composed of six canonical RNA-binding domains, including two RNA recognition motif (RRM) domains and four K homology (KH) domains^[@R17],\ [@R18]^. Besides *IGF2*, a few other well-known mRNAs (e.g., *MYC*, *ACTIN and LIN28B*) have been reported as targets of IGF2BPs^[@R19]--[@R21]^. However, the exact molecular mechanisms by which IGF2BPs recognize and regulate expression of their targets remain elusive. Here we provide compelling evidence showing that IGF2BPs preferentially recognize m^6^A-modified mRNAs and promote the stability (and likely also translation) of thousands of potential mRNA targets (including *MYC*) in an m^6^A-dependent manner, thereby globally affecting gene expression output. Furthermore, as m^6^A readers, IGF2BPs play oncogenic roles in cancer cells, likely by stabilizing methylated mRNAs of oncogenic targets (e.g., *MYC*).

RESULTS {#S3}
=======

Identification of IGF2BPs as m^6^A-binding proteins {#S4}
---------------------------------------------------

To identify m^6^A-binding proteins, we applied two independent methods: (i) using methylated single-stranded RNA bait (ss-m^6^A, with the consensus sequence GG(m^6^A)CU) or unmethylated control RNA (ss-A) for RNA pull-down ([Fig. 1a](#F1){ref-type="fig"} and [Supplementary Fig. 1a](#SD2){ref-type="supplementary-material"}), followed by mass spectrometry analysis^[@R2]^; (ii) developing a computational pipeline for screening potential m^6^A binding proteins by using published RNA-binding protein (RBP) CLIP-seq datasets and known m^6^A modification sites^[@R3]^. All three IGF2BP proteins were identified by mass spectrum and confirmed to selectively bind the methylated bait (ss-m^6^A) with a 3--4 fold higher affinity than the unmethylated control (ss-A) ([Fig. 1a](#F1){ref-type="fig"} and [Supplementary Fig. 1b](#SD2){ref-type="supplementary-material"}), and the binding seems to be independent of RNA secondary structure ([Supplementary Fig. 1c](#SD2){ref-type="supplementary-material"}). Similar to endogenous proteins, recombinant IGF2BP proteins purified from human cells also preferentially bound to methylated RNA probe over the unmethylated one ([Supplementary Fig. 1d and 1e](#SD2){ref-type="supplementary-material"}). In addition to ss-m^6^A, IGF2BPs also preferentially bound to methylated hairpin RNA (hp-m^6^A) probes over control (hp-A) probes ([Supplementary Fig. 1f and 1g](#SD2){ref-type="supplementary-material"}). Meanwhile, our computational pipeline revealed that all three IGF2BPs were among the top 15 of 112 RBPs in terms of both the significance ([Fig. 1b](#F1){ref-type="fig"}) and the frequency ([Supplementary Fig. 1h](#SD2){ref-type="supplementary-material"}) of m^6^A motifs enriched in their RNA binding sites. Thus, IGF2BP proteins are potential direct m^6^A-binding proteins.

We then overexpressed FLAG-tagged IGF2BPs in HEK293T cells and immunoprecipitated ribonucleoprotein complexes to evaluate the *in cellulo* binding. A significant enrichment of m^6^A modifications in FLAG-IGF2BPs-bound RNA was observed ([Fig. 1c](#F1){ref-type="fig"} and [Supplementary Fig. 1i](#SD2){ref-type="supplementary-material"}), similar to that in RNA immunoprecipitates (RIP) of endogenous IGF2BPs ([Supplementary Fig. 1j](#SD2){ref-type="supplementary-material"}). Sequencing purified RNA from FLAG-RIP samples identified more than 5000 genes from each RIP sample; among them, over 50% overlapped with published PAR-CLIP-seq targets^[@R22]^ (P\<5e-324, Fisher's exact test; [Fig. 1d](#F1){ref-type="fig"}). The 3747, 3211 and 3914 transcripts identified by both RIP and PAR-CLIP methods can be considered as high-confidence targets of IGF2BP1, IGF2BP2 and IGF2BP3, respectively ([Fig. 1d](#F1){ref-type="fig"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The three IGF2BP proteins shared 2149 (55%--70%) high-confidence RNA targets ([Fig. 1e](#F1){ref-type="fig"}). All three IGF2BPs preferentially bind to the "UGGAC" consensus sequence containing the "GGAC" m^6^A core motif ([Fig. 1f](#F1){ref-type="fig"}), and more than 80% of the high-confidence targets contain at least one m^6^A peak as detected by m^6^A-seq^3^ ([Fig. 1g](#F1){ref-type="fig"}). Moreover, most of the IGF2BP binding sites (92%) are located in protein-coding transcripts (i.e., mRNAs) and highly enriched near stop codons and in 3′ UTRs, coinciding with the m^6^A distribution ([Fig. 1h--1j](#F1){ref-type="fig"}). In addition, we analyzed ENCODE eCLIP-seq data in HepG2 cells and human embryonic stem cells (hESCs), and found that the "UGGAC" motif was also enriched in the targets of IGF2BPs in both cell types ([Supplementary Fig. 1k and ll](#SD2){ref-type="supplementary-material"}).

METTL3 and METTL14 are two critical components of the methyltransferase complex catalyzing methylation at *N^6^*-adenosine. We performed CLIP of Flag-tagged IGF2BP2 and IGF2BP3 in HEK293T cells with or without *METTL14* knockdown. Four representative high confidence targets, including *MYC*, *FSCN1*, *TK1*, and *MARCKSL1*, exhibit strong binding with IGF2BPs around their m^6^A motifs in control cells ([Fig. 1k](#F1){ref-type="fig"}). Such binding was largely impaired upon *METTL14* knockdown ([Fig. 1k](#F1){ref-type="fig"}), suggesting the requirement of cellular m^6^A modification for the binding. Taken together, these data demonstrated the role of IGF2BPs as direct m^6^A binding proteins *in vitro* and *in cellulo*.

Silencing of IGF2BPs globally down-regulates target gene expression {#S5}
-------------------------------------------------------------------

We next conducted RNA-seq in individual *IGF2BP* knockdown and control HepG2 cells ([Supplementary Fig. 2a](#SD2){ref-type="supplementary-material"}). The global transcripts were grouped into non-targets, CLIP targets and CLIP+RIP targets according to their binding by IGF2BPs in HEK293T cells (see [Fig. 1d](#F1){ref-type="fig"}), considering the availability of CLIP data for all three IGF2BPs in this cell line. Knockdown of individual IGF2BPs globally and preferentially inhibited expression of CLIP targets and especially CLIP+RIP targets, with much more CLIP+RIP targets being down-regulated than up-regulated ([Fig. 2a and 2b](#F2){ref-type="fig"}). Gene set enrichment analysis (GSEA) also showed that genes highly expressed in the control groups were enriched with the IGF2BP CLIP+RIP targets (FDR\<0.05, [Supplementary Fig. 2b](#SD2){ref-type="supplementary-material"}). Functional annotation indicated that target genes with reduced expression were enriched in DNA replication, cell cycle, proliferation and cancer related biological processes and pathways ([Supplementary Fig. 2c](#SD2){ref-type="supplementary-material"}). In addition, an enrichment of cell cycle genes and MYC target genes was observed in control vs. shIGF2BPs ([Supplementary Fig. 2d](#SD2){ref-type="supplementary-material"}). The down-regulation of representative targets was confirmed by qPCR ([Fig. 2c](#F2){ref-type="fig"}).

To determine whether the expression of IGF2BP targets is also affected by cellular m^6^A level, we performed m^6^A-seq and RNA-seq in control or *METTL14* knockdown HepG2 cells. Upon *METTL14* knockdown, 1516 genes showed reduced m^6^A modifications (i.e., m^6^A-Hypo genes; fold change (FC)\<0.667). Among these genes, 418 had reduced (i.e., m^6^A-Hypo-down genes; FC\<0.8) mRNA levels whereas 335 had increased levels (i.e., m^6^A-Hypo-up genes; FC\>1.2) ([Fig. 2d](#F2){ref-type="fig"}). As expected, IGF2BP high-confidence targets showed a global and significant reduction in mRNA level upon *METTL14* knockdown ([Fig. 2e](#F2){ref-type="fig"}). Expression of individual targets, including *FSCN1*, *TK1*, *MARCKSL1*, and *MYC*, was confirmed by qPCR to be significantly down-regulated upon *METTL3* or *METTL14* knockdown ([Fig. 2f](#F2){ref-type="fig"}). Similar changes were observed for *FSCN1* and *MYC*, two shared targets of IGF2BPs and YTHDF2, in *IGF2BP1/YTHDF2* double knockdown cells ([Supplementary Fig. 2e](#SD2){ref-type="supplementary-material"}). On the other hand, the m^6^A-Hypo-down genes were globally down-regulated upon *IGF2BPs* knockdown, as compared to their non-target counterparts ([Supplementary Fig. 2f](#SD2){ref-type="supplementary-material"}). The correlated regulation of gene expression by IGF2BPs and METTL14 indicates that IGF2BPs are responsible for the expression output of m^6^A-regulated genes.

Regulation of mRNA stability by IGF2BPs {#S6}
---------------------------------------

mRNA stability profiling in HepG2 cells revealed that high-confidence targets of IGF2BP1-3 tend to have longer half-lives (*p*\<0.001) than their non-target counterparts ([Fig. 3a](#F3){ref-type="fig"}), whereasYTHDF2 targets tend to have shorter half-lives ([Supplementary Fig. 3a](#SD2){ref-type="supplementary-material"}). Similar results were observed in Hela cells^[@R10]^ ([Fig. 3a](#F3){ref-type="fig"} and [Supplementary Fig. 3a](#SD2){ref-type="supplementary-material"}). Since IGF2BP3 silencing affected target gene expression most potently ([Fig. 2a and 2b](#F2){ref-type="fig"}), we performed mRNA stability profiling in *IGF2BP3* knockdown cells. The median half-life of IGF2BP3 high-confidence targets as well as CLIP targets were significantly reduced in IGF2BP3-depleted cells to approximately 50% of that in control cells ([Fig. 3b and 3c](#F3){ref-type="fig"}, and [Supplementary Fig. 3b and 3c](#SD2){ref-type="supplementary-material"}). Accelerated mRNA decay of *MYC*, *FSCN1*, *TK1*, and *MARCKSL1* upon knockdown of each *IGF2BP* was confirmed in HepG2 cells ([Fig. 3d](#F3){ref-type="fig"} and [Supplementary Fig. 3d](#SD2){ref-type="supplementary-material"}) and human cord blood CD34^+^ cells ([Supplementary Fig. 3e](#SD2){ref-type="supplementary-material"}). Furthermore, the stability of *MYC*, *FSCN1*, *TK1*, and *MARCKSL1* mRNAs was also reduced when m^6^A writers were silenced ([Fig. 3e](#F3){ref-type="fig"} and [Supplementary Fig. 3f](#SD2){ref-type="supplementary-material"}).

To identify cofactors of IGF2BPs that may enhance stability of mRNA targets, we pulled down the IGF2BP2 complexes and conducted mass spectrometry analysis. Notably, ELAV like RNA binding protein 1 (ELAVL1, also known as HuR), matrin 3 (MATR3), and poly(A) binding protein cytoplasmic 1 (PABPC1), three known mRNA stabilizers^[@R23]--[@R26]^, were identified. Western blotting confirmed their binding to ectopically expressed IGF2BPs in HEK293T cells ([Fig. 3f](#F3){ref-type="fig"}), consistent with previous reports^[@R21],\ [@R27]^. Moreover, co-localization of HuR and IGF2BPs was observed in cytoplasmic granules ([Fig. 3g](#F3){ref-type="fig"}), highly likely in P-bodies, as shown by DCP1A (i.e., P-body marker) staining ([Fig. 3h](#F3){ref-type="fig"}). Thus, IGF2BPs likely recruit RNA stabilizers to promote the stability of their mRNA targets.

Stress granules are a second type of cytoplasmic mRNP granule thought to protect mRNAs from harmful conditions, and the protected mRNAs could be returned for translation after stress is relieved. We found that IGF2BPs were well co-localized with the stress granule marker TIAR, but only partially overlapped with DCP1A under heat shock ([Supplementary Fig. 3g and 3h](#SD2){ref-type="supplementary-material"}), which is consistent with previous reports ^[@R28],\ [@R29]^ and further reveals the roles of IGF2BPs in mRNA stabilization and storage during stress. Thus, our data indicate that IGF2BPs can promote RNA stability and/or increase mRNA storage in a dynamic manner under different physiological conditions.

Polysome profiling showed that FLAG-IGF2BP1 and FLAG-IGF2BP2 were present in most of the sucrose gradient fractions, while FLAG-IGF2BP3 was accumulated in 60S and 40S ([Supplementary Fig. 4a](#SD2){ref-type="supplementary-material"}). A similar distribution of endogenous IGF2BP1/2/3 proteins was observed in HepG2 cells ([Supplementary Fig. 4b](#SD2){ref-type="supplementary-material"}). Interestingly, HuR was detected along with each FLAG-tagged IGF2BP ([Supplementary Fig. 4a](#SD2){ref-type="supplementary-material"}). Moreover, knockdown of *IGF2BP1* in HEK293T cells significantly reduced *MYC* mRNA in the translating pool ([Supplementary Fig. 4c](#SD2){ref-type="supplementary-material"}, fractions 13--18), suggesting a role of IGF2BPs in the active translation of their target genes. In agreement with the localization of IGF2BPs to stress granules during heat shock, IGF2BP2 shifted to non-ribosome fractions, and was found to gradually return to ribosome fractions during recovery from heat shock ([Supplementary Fig. 4d](#SD2){ref-type="supplementary-material"}).

IGF2BPs regulate *MYC* expression in an m^6^A-dependent manner {#S7}
--------------------------------------------------------------

To determine whether IGF2BP-mediated gene regulation is m^6^A-dependent, we chose *MYC*, a well-known target of IGF2BP1^[@R19],\ [@R21],\ [@R30]^, for a systematic study. A \~250 nucleotide (nt) cis-acting element called coding region instability determinant (CRD) resides in the 3′-terminus of the *MYC* coding region and has been proved critical for IGF2BP1 binding^[@R30]^. As shown in [Figure 4a](#F4){ref-type="fig"}, m^6^A modifications are accumulated across *MYC* transcript, and the m^6^A peaks coincide well with IGF2BP binding sites. Notably, the CRD-containing region has a high abundance of m^6^A modifications that decreases remarkably upon *METTL14* knockdown ([Fig. 4a](#F4){ref-type="fig"}). By conducting RIP and gene-specific m^6^A assays, we confirmed the *in cellulo* IGF2BP binding ([Fig. 4b](#F4){ref-type="fig"} and [Supplementary Fig. 5a](#SD2){ref-type="supplementary-material"}) and m^6^A modification ([Fig. 4c](#F4){ref-type="fig"}), as well as METTL3 and METTL14 binding ([Fig. 4d](#F4){ref-type="fig"}), in CRD. Moreover, the m^6^A modifications in the consensus sites of the synthetic CRD RNA oligos greatly facilitated their binding by endogenous IGF2BPs ([Fig. 4e](#F4){ref-type="fig"}).

We next inserted the 249-nt wild-type or mutant CRD sequence into a firefly luciferase (Fluc) reporter ([Supplementary Fig. 5b](#SD2){ref-type="supplementary-material"}). Mutations in the m^6^A sites of CRD (CRD1 and CRD2 RNA oligos) dramatically abrogated the association with IGF2BP proteins *in vitro* ([Supplementary Fig. 5c](#SD2){ref-type="supplementary-material"}). As expected, ectopic IGF2BPs induced a significant increase in Fluc activity of wild-type reporter in a dose-dependent manner ([Supplementary Fig. 5d](#SD2){ref-type="supplementary-material"}). Such increase was largely impaired by mutations in the m^6^A consensus sites ([Fig. 4f](#F4){ref-type="fig"}, left, and [Supplementary Fig. 5b](#SD2){ref-type="supplementary-material"}). Consistently, relative *Fluc* mRNA level of CRD-wt, but not CRD-mut, was increased by *IGF2BP* overexpression ([Fig. 4f](#F4){ref-type="fig"}, right). RIP-qPCR demonstrated a strong binding of IGF2BPs with CRD-wt reporters and a much less or no binding with CRD-mut *in cellulo* ([Fig. 4g](#F4){ref-type="fig"}). Conversely, knockdown of individual *IGF2BPs*, similar to knockdown of *METTL14*, caused inhibited Fluc activity, which also relies on the presence of wild-type m^6^A motifs within CRD ([Fig. 4h and 4i](#F4){ref-type="fig"}). Noticeably, IGF2BPs-mediated increase of luciferase activity could be partially or completely blocked by *METTL14* knockdown ([Fig. 4j](#F4){ref-type="fig"}). Taken together, our data demonstrate that m^6^A modifications in CRD are required for the binding of IGF2BPs to *MYC* and for IGF2BP-mediated regulation of *MYC* expression.

Recognition of m^6^A by IGF2BPs' KH domains {#S8}
-------------------------------------------

RRM and KH, the RNA binding domains of IGF2BPs, are different from YTH domain, the known m^6^A binding domain^[@R2],\ [@R10],\ [@R14],\ [@R16]^. We constructed IGF2BP mutants with truncation of the two RRM domains, or with mutations of GxxG to GEEG in the KH domains as reported^[@R20]^ ([Fig. 5a](#F5){ref-type="fig"}), and showed KH domains (KH1-4) mutations, but not RRM truncation, completely abolished the interaction between IGF2BPs and ss-m^6^A probes ([Fig. 5b](#F5){ref-type="fig"} and [Supplementary Fig. 5e](#SD2){ref-type="supplementary-material"}). Interaction of IGF2BPs with ss-m^6^A probes was only partially reduced by KH1-2 di-domain mutation but was almost completely abolished by KH3-4 mutation ([Fig. 5b](#F5){ref-type="fig"}), indicating that the KH3-4 di-domain is indispensable for m^6^A recognition and binding while KH1-2 might play an accessory role. KH domain mutations including KH3-4 and KH1-4, but less likely KH1-2 mutation or RRM truncation, also impaired the binding of IGF2BP2 to hp-m^6^A probes ([Supplementary Fig. 5f](#SD2){ref-type="supplementary-material"}). Accordingly, mutation of KH3-4 interrupted the association of IGF2BPs with methylated CRD probes *in vitro* and with *MYC* CRD *in cellulo* ([Fig. 5c and 5d](#F5){ref-type="fig"}). Moreover, IGF2BP2-promoted luciferase expression of CRD-wt reporter was partially impaired by KH1-2 mutation and completely diminished by KH3-4 or KH1-4 mutations ([Fig. 5e](#F5){ref-type="fig"}).

IGF2BP1 was reported to play a role in stabilizing mRNA under stress conditions^[@R29],\ [@R31]^. We found that when Hela cells were exposed to heat shock at 42˚C for 1 hour, *MYC* mRNA was decreased to about 50% ([Fig. 5f](#F5){ref-type="fig"}). Overexpression of wild-type IGF2BPs significantly diminished the reduction of *MYC* mRNA; however, this protective effect was largely or completely impaired by the mutation in KH3-4 ([Fig. 5f](#F5){ref-type="fig"}). Collectively, these results demonstrate the essential roles of KH3-4 di-domains in IGF2BP binding to m^6^A-modified mRNAs and in regulation of target gene expression in both normal and stress conditions.

IGF2BPs play oncogenic roles in cancers as m^6^A readers {#S9}
--------------------------------------------------------

Detailed analysis of public databases from cBioPortal for Cancer Genomics (<http://www.cbioportal.org>) and The Cancer Genome Atlas (TCGA) (<http://cancergenome.nih.gov>) showed that all three IGF2BPs are frequently amplified or highly expressed in a variety of human cancers ([Supplementary Fig. 6a and 6b](#SD2){ref-type="supplementary-material"}). Given their similar effect on stabilizing oncogenic transcripts such as *MYC*, we assume that all three IGF2BPs could exert oncogenic functions in cancer. Indeed, knocking down of each individual *IGF2BPs* in Hela (cervical cancer) and HepG2 (liver cancer) cells significantly repressed MYC expression ([Fig. 6a](#F6){ref-type="fig"}) and inhibited cancer cell proliferation, colony formation ability, and cell migration/invasion ([Fig. 6b--6d](#F6){ref-type="fig"} and [Supplementary Fig. 6c--6e](#SD2){ref-type="supplementary-material"}), which mimics the effect of MYC silencing ([Supplementary Fig. 6f--6j](#SD2){ref-type="supplementary-material"}).

By utilizing the CRISPR-Cas9 system, we generated IGF2BPs-knockout (KO) cells ([Fig. 7a](#F7){ref-type="fig"}) and performed rescue experiments. The decreased proliferation and colony formation ability of KO cells could be reversed by forced expression of wild-type IGF2BPs, but not the KH3-4-mutants ([Fig. 7b and 7c](#F7){ref-type="fig"}), suggesting the oncogenic function of IGF2BPs relies on their role as m^6^A readers. Ectopic expression of MYC also restored the proliferative ability of IGF2BP-KO cells ([Fig. 7d](#F7){ref-type="fig"}), further supporting *MYC* as a critical target of IGF2BPs.

Discussion {#S10}
==========

The characterization of the YTH-domain-containing proteins as direct m^6^A readers^[@R2],\ [@R10],\ [@R14],\ [@R16]^ has provided profound insights into our understanding of effects of m^6^A modification on genetic information flow. Our findings add a distinct RNA binding protein family, IGF2BPs, into the catalogue of m^6^A readers, and reveal their roles in mRNA stabilization and translation ([Fig. 7e](#F7){ref-type="fig"}). Notably, over 3,000 mRNA transcripts were identified as targets of each individual IGF2BP protein, while over 5,000 mRNAs being targeted by at least one protein and more than 2,000 mRNAs being co-targeted by all three IGF2BPs. The binding sites of IGF2BPs are enriched with m^6^A motif "GGAC". Given that only around 7,000 mRNA transcripts are m^6^A modified in individual mammalian cells ^[@R2],\ [@R3]^ and that more than 80% of IGF2BP targets have at least one m^6^A peak ([Fig. 1g](#F1){ref-type="fig"}), IGF2BPs likely have a broad impact on m^6^A-associated gene regulation. Accordingly, reduction of cellular m^6^A levels upon *METTL14* knockdown impairs the *in cellulo* binding of Flag-IGF2BP2/3 to their RNA targets. Furthermore, we demonstrated that IGF2BPs bind directly to *MYC* CRD and promote MYC expression in an m^6^A-dependent manner.

The direct binding of IGF2BPs to m^6^A RNAs through their KH domains was demonstrated both *in vitro* and *in cellulo*. KH domain is an evolutionarily conserved RNA recognition element found in several proteins, such as FMR1, HNRPK, and PTBP1 ^[@R32]^. KH domains in IGF2BPs were responsible for the recognition and binding of some specific mRNAs, including *ACTIN*, *MYC*, and *IGF2*^[@R17],\ [@R33],\ [@R34]^. Our work reveals a new, m^6^A-dependent binding mode on top of the primary sequence. We show that KH domains, especially the KH3-4 di-domain, are critical for the binding of IGF2BPs to m^6^A-modified RNAs. Nonetheless, KH3-4 peptides alone showed poor selectivity for m^6^A RNA compared to full length proteins (data not shown), consistent with previous reports that post-translational modifications in the KH3-4 flanking regions may be important for IGF2BP selectivity^[@R17],\ [@R35]^. Future structural studies are warranted to understand how specific KH domains bind to m^6^A-modified RNAs. It will also be interesting to investigate other KH domain proteins as potential m^6^A-binding readers.

Our RNA stability profiling revealed that IGF2BPs stabilize target RNAs. The opposite role of IGF2BPs versus YTHDF2 imposes an additional layer of complexity on m^6^A function. It is possible that IGF2BPs and YTHDF2 recognize different targets, or compete for the same m^6^A sites to fine-tune expression of shared targets. In fact, YTHDF2 binding sites show a lower density in the 3′UTRs than in the coding regions^[@R10]^, which is distinct from IGF2BP binding sites ([Fig. 1h](#F1){ref-type="fig"}). Analysis of the ENCODE PAR-CLIP data revealed only a very small proportion (0.85%--1.20%) of IGF2BP binding sites being shared by YTHDF2 ([Supplementary Fig. 7a](#SD2){ref-type="supplementary-material"}). Moreover, a consensus of "GAAC" besides "GGAC" was found from all significant YTHDF2 binding sites ([Supplementary Fig. 7b](#SD2){ref-type="supplementary-material"}). In addition, we found that IGF2BP binding sites have a significant lower guanine-cytosine (GC) content than YTHDF2 binding sites ([Supplementary Fig. 7c and 7d](#SD2){ref-type="supplementary-material"}), suggesting that local nucleotide composition may also contribute to the binding preference of different readers. Together, these data suggest that IGF2BPs and YTHDF2 have distinct pattern in target recognition and regulation.

The mRNA stabilizing function of IGF2BPs was also supported by its cofactors, HuR and MATR3. Particularly, HuR was previously identified as an indirect m^6^A binding protein, which increased stability of bound RNA and blocked microRNA targeting^[@R8],\ [@R25],\ [@R36]^. Interestingly, we showed here that HuR was colocalized with IGF2BPs in P-bodies, locations for mRNA fate decision^[@R37]--[@R39]^. Our findings suggest that HuR could be recruited by IGF2BPs to protect m^6^A-containing mRNAs from degradation and facilitate their translation ([Fig. 7e](#F7){ref-type="fig"}). We found that IGF2BPs colocalize with stress granules and shuttle between ribosome and non-ribosome fractions during heat shock and recovery, suggesting a role of IGF2BPs in mRNA translation in stress response. Collectively, IGF2BPs can promote stability by inhibiting mRNA degradation or enhancing mRNA storage under stress, and facilitate their translation ([Fig. 7e](#F7){ref-type="fig"}). We recently reported that METTL14 promotes the stability and translation of *MYC* mRNA and plays an essential oncogenic role in leukemia^[@R40]^, which is likely also attributed to IGF2BP-mediated, m^6^A-dependent regulation of MYC expression.

Dysregulation of IGF2BPs could result in abnormal accumulation of oncogenic products such as MYC, and therefore support the malignant state of cancer cells. Consistent with the frequent amplification of *IGF2BP* genes in various types of cancers, our finding that IGF2BPs exhibit oncogenic roles as m^6^A readers demonstrates the functional importance of IGF2BPs and their associated m^6^A reading processes in tumorigenesis, and highlights the therapeutic potential of targeting IGF2BPs in cancers.

METHODS {#S11}
=======

Plasmids and siRNAs {#S12}
-------------------

pcDNA3-based vectors encoding wild-type and KH domain mutant FLAG-tagged chicken ZBP1 (refer to as IGF2BP1), human IGF2BP2 and IGF2BP3 were kindly provided by Dr. Hüttelmaier (Martin-Luther-University, Germany). RRM domain truncation of IGF2BP2 (IGF2BP2-ΔRRM) was produced by PCR using the Q5 Site Directed Mutagenesis Kit (NEB) with Forward primer 5′-GAAGAGGTGAGCTCCCCT-3′ and Reverse primer 5′-GAATTCCTTGTCGTCGTCC-3′. The plasmid encoding human MYC (pCDNA3-HA-HA-humanCMYC) was obtained from Addgene. The TRC lentiviral vectors encoding shRNAs against IGF2BP1 (TRCN0000075149 and TRCN0000075152), IGF2BP2 (TRCN0000149002 and TRCN0000148565), IGF2BP3(TRCN0000074677 and TRCN0000074673), METTL3 (TRCN0000034715) and METTL14 (TRCN0000015933) and their non-specific control (shNS, RHS6848) were purchased from GE Dharmacon (Lafayette, CO), while the packing vectors, pMD2.G, pMDLg/pRRE and pRSV-Rev were obtained from Addgene. The MYC siRNA was purchased from Santa Cruz Biotechnology (Santa Cruz, CA), while the HuR siRNA was from GE Dharmacon.

Cell culture and transfection {#S13}
-----------------------------

The human hepatocellular carcinoma cell line HepG2 (ATCC HB-8065) was maintained in EMEM medium (ATCC) supplemented with 10% FBS (Invitrogen, Carlsbad, CA), 2 mM L-Glutamine and 1% penicillin-streptomycin. HEK293T and Hela cells were grown in DMEM medium (Invitrogen) containing 10% FBS, 2 mM L-Glutamine and 1% penicillin-streptomycin. All cell lines were purchased from the American Type Culture Collection (ATCC) and were not authenticated by ourselves. All cell lines were routinely tested for mycoplasma contamination. These cell lines were not listed in the database of commonly misidentified cell lines maintained by ICLAC. For heat shock treatment, Hela cells were incubated at 42 °C for 1 hour. Plasmids and siRNAs were transfected into cells with Lipofectamine 2000 (Invitrogen) according to the instructions of the manufacturer.

Isolation and lentiviral infection of CD34^+^ cells {#S14}
---------------------------------------------------

Cord blood of healthy donors was obtained from Cincinnati Children's Hospital Medical Center (CCHMC, Cincinnati, USA) and subjected to isolation of mononuclear cells (MNCs) using Ficoll-Paque PLUS (GE Healthcare Life Sciences). Human CD34^+^ hematopoietic stem/progenitor cells (HSPCs) were then purified from MNCs by using human CD34 MicroBead Kit (Miltenyi Biotec, Auburn, CA). The CD34^+^ cells were cultured in StemSpan^™^ SFEM medium (StemCell Technologies, Vancouver, Canada) supplemented with 1% Lipid Mixture 1 (L0288, Sigma-Aldrich, St. Louis, MO), 2 mmol/L L-glutamine, 1% penicillin-streptomycin, 100 ng/mL SCF, and 2 ng/mL IL-3. Cells were infected with concentrated lentiviral particles through two rounds of "spinoculation".

RNA affinity chromatography and nLC-ESI-MS/MS {#S15}
---------------------------------------------

Biotin-labelled RNA oligonucleotides containing adenosine or m^6^A were synthesized by GE Dharmacon. The hpRNA baits were denatured at 99 °C for 10 minutes and slowly cooled down to room temperature to allow the formation of stem-loop structure before use. The ssRNA baits were denatured at 99 °C for 10 minutes and put on ice immediately unless otherwise specified. Each RNA oligonucleotide (0.4 pmol, unless otherwise specified) was immobilized onto 50 μl streptavidin magnetic beads (Thermo Fisher Scientific, BufferRockford, IL) in binding buffer (20 mM Tris, 200 mM NaCl, 6 mM EDTA, 5 mM potassium fluoride, 5 mM β-glycerophosphate, 2 μg/ml aprotinin at pH 7.5) at 4 °C for 4 hours. RNA bait-conjugated streptavidin beads were then incubated with 200 μg of HEK293T nuclear extract or 0.5 μg to 1 ug of human recombinant proteins in binding buffer in a final volume of 400 μl overnight at 4 °C. After extensive washing, RNA--protein complexes were dissolved in 1x SDS buffer, separated under denaturing conditions on 10% SDS-polyacrylamide Bis-Tris gels and detected by silver staining (Thermo Fisher Scientific) or Western blot analysis. For mass spectrometry analysis, proteins in gel slices were digested with trypsin. The recovered peptides were introduced into an Eksigent (Dublin, CA) nanoLC.ultra nanoflow system attached to a TripleTOF 5600 plus (Sciex, Toronto, Canada) for nLC-ESI-MS/MS analyses.

Protein expression and purification {#S16}
-----------------------------------

Flag-tagged IGF2BP1, IGF2BP2 and IGF2BP3 were expressed in HEK293T cells. For each protein, four 15 cm dishes of cells were prepared and lysed in 4 ml lysis buffer (50 mM Tris-HCl pH 7.5, 300 mM KCl, 0.5% NP-40, 5% Glycerol, 5 μg/ml DNase I, 1% RNase T1/A, 1% protease inhibitor, 1 mM DTT) at 4 °C for 1 hour and sonicated (5 seconds on, 25 seconds off, 24 cycles). The lysate was then cleared by centrifuge at 4 °C. The proteins were affinity purified using 40 μl anti-Flag M2 resin (Sigma-Aldrich) at 4 °C for 2 hour. After extensive wash with wash buffer (50 mM Tris-HCl, pH 7.5. 300 mM KCl, 5% Glycerol, 1 mM DTT), proteins were eluted in 500 μl 1x Flag elution solution (0.5 mg/ml Flag peptide in wash buffer) at 4 °C for 1 hour. Protein purity was verified with SDS-PAGE followed by coomassie staining.

Electrophoretic mobility shift assay/gel shift assay (EMSA) {#S17}
-----------------------------------------------------------

The Cy5.5-labelled RNA oligonucleotides \[ss-A: Cy5.5-CGUCUCGGACUCGGACUGCU; ss-m^6^A: Cy5.5-CGUCUCGG(m^6^A)CUCGG(m^6^A)CUGCU\] with the same sequences of biotin-labelled ss-A and ss-m^6^A were synthesized by GE Dharmacon. The gel shift assay was performed as previously described^[@R10]^. Briefly, RNA probes were denatured by heating at 65 °C for 5 min and slowly cooling down to room temperature. For each reaction, 1 μl RNA probes (4 nM final concentration) and 1 μl protein (10x of the concentration gradient indicated in [Fig. S1d](#SD2){ref-type="supplementary-material"}) were incubated in 8 μl binding buffer (10 mM Tris-HCl pH7.5, 50 mM KCl, 1 mM EDTA, 0.05% Triton-X-100, 5% glycerol, 1 mM DTT and 40 U/ml RNasin) on ice for 30 min. The RNA-protein mixtures were separated in 5% native polyacrylamide gels (in 0.5x Tris-borate-EDTA buffer) at 4 °C for 60 min at 13 V/cm. The fluorescence signal was visualized by Odyssey Imaging Systems (LI-COR Biosciences) and quantified by ImageMaster TotalLab (GE Healthcare). The dissociation constant (*K*~d~) was calculated with nonlinear curve fitting (Function one site-specific binding) using GraphPad Prism with y=B~max~\*x/(*K*~d~+x), where y is the ratio of \[RNA-protein\]/(\[free RNA\]+\[RNA-protein\]), x is the input protein concentration, and B~max~ is set to 1.

m^6^A dot blot {#S18}
--------------

The m^6^A dot blot assay was conducted as previously described ^[@R12]^. Briefly, the indicated amount of total cellular RNA or synthesized RNA oligonucleotide was denatured in 3-fold volume of RNA incubation buffer (65.7% fomamide, 7.77% formaldehyde and 1.33x MOPS) at 65 °C for 5 min, followed by chilling on ice and mixing with 1 volume of 20x SSC. RNA samples were applied to Amersham Hybond-N+ membrane (GE Healthcare, Piscataway, NJ) with a Bio-Dot Apparatus (Bio-Rad, Hercules, CA). After UV crosslinking, the membrane was stained with 0.02% methylene blue (MB) in 0.3M sodium acetate. The membrane was then washed with 1x PBST buffer, blocked with 5% non-fat milk in PBST, and incubated with anti- m^6^A antibody (\#202003, 1:1000; Synaptic Systems, Göttingen, Germany) overnight at 4 °C. After incubating with HRP-conjugated anti-rabbit IgG secondary antibody (Santa Cruz Biotechnology), the membrane was visualized using Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare).

Western blotting {#S19}
----------------

Cells were lysed using 1x SDS buffer and sonicated. Equal amounts of proteins were loaded and separated by 10% SDS-PAGE, transferred to polyvinylidene fluoride membranes, and detected by immunoblotting with the Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific) or Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare). Antibodies used for Western blotting were as follows unless otherwise specified: IGF2BP1(IMP1, clone D33A2, \#8482), IGF2BP2 (IMP2, clone D4R2F, \#14672), MYC (clone D3N8F, \#13987), HuR (ELAVL1, clone D9W7E, \#12582) were from Cell Signaling Technology (CST, Beverly, MA), IGF2BP3 (IMP3, A303-426A) and MATRIN3 (A300-591A-T) were from Bethyl Laboratories (Montgomery, TX), and FLAG (M2, F3165) was from Sigma-Aldrich (St. Louis, MO). GAPDH (sc-47724, Santa Cruz) was used as a loading control.

Prediction of m^6^A binding proteins {#S20}
------------------------------------

We developed a computational pipeline to discover the potential m^6^A binding proteins from ENCODE and published RBP-CLIP data sets generated by various CLIP methods, including HITS-CLIP, PAR-CLIP, eCLIP, iCLIP and irCLIP. The CLIP-seq peaks of each RBP were intersected with known m^6^A sites ^[@R41]^ to calculate the ratio between the number of peaks overlapping with m^6^A-peak sites and total number of peaks (m^6^A-containing peak number/total peak number). These peaks were imported into HOMER software ^[@R42]^ for *de novo* motif identification. The potential m^6^A binding proteins should meet the following requirements: (i) the ratio (m^6^A-containing peak number/total peak number) should be larger than 10%; and (ii) for the identified motifs of each RBP, the p-value should be less than 1e-35. Based on this pipeline, all the top *de novo* motifs could be identified unbiasedly. Nevertheless, because we are interested in identification of m^6^A-binding proteins, we further focused on the proteins that have top motif(s) containing 'GGAC', which represents the most common m^6^A consensus sequence.

LC-MS/MS {#S21}
--------

Fifty to one hundred ng of mRNA were digested by nuclease P1 (1U, Wako Pure Chemical, Osaka, Japan) in 25 μl of buffer containing 20 mM of NH~4~OAc (pH = 5.3) at 42°C for 2 h, followed by the addition of NH~4~HCO~3~ (1 M, 3 μl, freshly made) and alkaline phosphatase (1 U, Sigma). After an additional incubation at 37°C for 2 h, the sample was diluted to 50 μl and filtered (0.22 μm pore size, 4 mm diameter, Millipore), and 5 μl of the solution was injected into LC-MS/MS. Nucleosides were separated by reverse phase ultra-performance liquid chromatography on a C18 column with on-line mass spectrometry detection using an Agilent 6410 QQQ triple-quadrupole LC mass spectrometer in positive electrospray ionization mode. The nucleosides were quantified by using retention time and the nucleoside to base ion mass transitions of 284 to 152 (G), 282.1 to 150.1 (m^6^A), 268 to 136 (A), 245 to 113.1 (U), and 244 to 112 (C). Quantification was performed in comparison with the standard curve obtained from pure nucleoside standards running with the same batch of samples. The m^6^A level was calculated as the ratio of m^6^A to A or the ratio of m6A to (A+U+C+G) based on the calibrated concentrations.

RIP-LC-MS/MS {#S22}
------------

The RNA immunoprecipitation (RIP) procedure was reported previously ^[@R10]^. Three 15 cm dishes of confluent HEK293T cells transiently overexpressing Flag tagged IGF2BP (1, or 2, or 3) were subjected to RIP procedure. Input, flow-through, and IGF2BP-bound RNA were purified with Trizol reagent. mRNA from the three portions was further purified by depleting rRNA with RiboMinus Eukaryote Kit v2 (Ambion, Austin, TX) followed by depleting tRNA with RNA Clean and Concentrator-5 (Zymo Research, Orange, CA). 50 ng purified mRNA of each sample was subjected to LC-MS/MS quantification of m^6^A levels as reported previously ^[@R10]^.

RNA immunoprecipitation (RIP) {#S23}
-----------------------------

RNA immunoprecipitation was performed as previously described ^[@R43]^ with some modifications. Briefly, cells seeded in 10 cm dish at 70--80% confluency were cross-linked by UV and harvested by trypsinization. Nuclear extraction was isolated and sonicated. One microgram of FLAG (F3165, Sigma-Aldrich), IGF2BP1 (\#8482, CST), or IGF2BP2 (\#14672, CST) antibody or a corresponding control IgG (mouse IgG (CS200621, Millipore) for Flag, rabbit IgG (\#NI01, Millipore) for IGF2BP1 and IGF2BP2) was conjugated to Protein A/G Magnetic Beads (Thermo Fisher Scientific) by incubation for 4 hours at 4 °C, followed by 3x wash and incubation with pre-cleared nuclear extraction in RIP buffer \[150 mM KCl, 25 mM Tris (pH 7.4), 5 mM EDTA, 0.5 mM DTT, 0.5% NP40, 1x protease inhibitor\] at 4 °C overnight. After washing with RIP buffer for three times, beads were resuspended in 80 μl PBS, followed by DNA digestion at 37 °C for 15 min and incubation with 50 μg of Proteinase K (Thermo Fisher) at 37 °C for 15 min. Input and co-immunoprecipitated RNAs were recovered by TRIzol (Invitrogen) extraction and analyzed by qPCR or RNA-seq.

Crosslinking and Immunoprecipitation (CLIP) {#S24}
-------------------------------------------

CLIP was performed following previously reported protocol ^[@R10]^ with some modifications. HEK293T cells seeded in four 15-cm plates at approximately 80% confluency were treated with 200 μM 4-thiouridine (4-SU). After 16 hours, cells were washed with ice-cold PBS, crosslinked with 150 mJ/cm^2^ of 365 nm ultraviolet light and harvested by trypsinization. Nuclear extraction was isolated and sonicated. Two to three milligram of nuclear lysates were serially digested by 0.05U/μl DNase RQ1 at 37 °C for 5 min, and 0.2U/μl RNase T1 at 22 °C for 15 min. Ten microgram of FLAG (F3165, Sigma-Aldrich) or IGF2BP2 (\#14672, CST) antibody was conjugated to protein A/G magnetic beads and incubated with nuclear lysates in RIP buffer at 4 °C overnight. After washing with RIP buffer for three times, a second round of RNase T1 digestion was conducted under 50U/μl at 22 °C for 15 min. Input and immunoprecipiated RNAs were recovered and analyzed by qPCR.

RNA-seq {#S25}
-------

Total RNA was isolated from IGF2BP knockdown or control HepG2 cells using miRNeasy Kit (Qiagen). PolyA RNA was subsequently purified from 50--100 ng total RNA using NEBNext Poly(A) mRNA Magnetic Isolation Module. NEBNext Ultra Directional RNA Library Prep Kit (New England BioLabs, Ipswich, MA) was used for library preparation. Each group was sequenced in triplicate.

RNA stability assay and sequencing for mRNA lifetime {#S26}
----------------------------------------------------

HepG2 cells with stably expressed shRNAs against IGF2BPs or shNS were seeded into 6-well plates to get 50% confluency after 24 hours. Cells were treated with 5 μg/ml actinomycin D and collected at indicated time points. The total RNA was extracted by miRNeasy Kit (Qiagen) and analyzed by RT-PCR and RNA-seq. For RNA sequencing, equal amount of ERCC RNA spike-in control (Thermo Fisher Scientific) was added to the total RNA samples as internal controls before library construction. Sequencing libraries were prepared using NEBNext Ultra Directional RNA Library Prep Kit. RNA stability profiling was generated from two biological replicates.

The turnover rate and half-life of mRNA was estimated according to previously published paper^[@R44]^. Since actinomycin D treatment results in transcription stalling, the change of mRNA concentration at a given time (dC/dt) is proportional to the constant of mRNA decay (K~decay~) and mRNA concentration (C), leading to following equation: $$\text{dC}/\text{dt} = - k_{\text{decay}}C$$

Thus the mRNA degradation rate K~decay~ was estimated by: $$\text{Ln}\,(C/C_{0}) = - k_{\text{decay}}t$$

To calculate the mRNA half-life (t~1/2~), when 50% of mRNA is decayed (ie. C/C~0~=1/2), the equation was: $$\text{Ln}(1/2) = - k_{\text{decay}}t_{1/2}$$

From where: $$t_{1/2} = \text{ln}2/k_{\text{decay}}$$

m^6^A-seq {#S27}
---------

Total RNA was extracted by homogenizing cells in TRIzol reagent and purifying with Direct-zol RNA MiniPrep kit (Zymo). mRNA was further purified using Dynabeads mRNA purification kit (Thermo). RNA fragmentation was performed by sonication at 10 ng/μl in 100 μl RNase-free water using Bioruptor Pico (Diagenode) with 30s on/30s off for 30 cycles. m6A-IP and library preparation were performed according to the published protocol ^[@R2]^. Sequencing was carried out on Illumina HiSeq 2000 according to the manufacturer's instructions.

Sequencing data analysis {#S28}
------------------------

### For RIP-seq data {#S29}

Samples were sequenced by Illumine Hiseq 1000 with a single end 51-bp read length. The RIP-seq reads were mapped to human genome version hg19 by Tophat2 version 2.0.13 with default settings ^[@R45]^. Differential gene expression was calculated by Cuffdiff version v2.2.1 ^[@R46]^. The RIP targets were defined as genes with RPKM \>= 1, IP/input \>= 2, and p-value \< 0.05.

### For PAR-CLIP data {#S30}

The IGF2BPs PAR-CLIP data were obtained from the public database GEO (Accession No. GSE21918) ^[@R22]^. The adapters were trimmed by using cutadapt version 1.9.1 ^[@R47]^. The processed reads were mapped to human genome version hg19 by bowtie version 1.1.2 with parameters: --v 3 --m 5 \--best \--strata ^[@R48]^. The mapped results were analyzed by PARalyzer v1.5 with default settings ^[@R49]^. The results were further filtered by ModeScore \>= 0.6. For peaks that were larger than 50 nt, we extracted 50 nt centered on ModeLocation site. GENCODE v24 was used to annotate the filtered peaks, and finally the PAR-CLIP target genes of IGF2BP1 (7511), IGF2BP2 (7974) and IGF2BP3 (9228) were identified. We then chose peaks overlapping with RIP targets for *de novo* motif analysis using HOMER software with default RNA analysis parameters.

### For eCLIP data {#S31}

To identify IGF2BP footprints, all mapped reads to consecutive genomic peaks were first assembled. Significant peaks were calculated by determining read-number cutoffs using the Poisson distribution as described by Zisoulis et al ^[@R50]^. The Poisson distribution assumes all intervals are independent and have equal probability of an occurrence happening. Peaks with significant high read-number values (p\<10e-5 and the minimum peak height \>= 10) and occurring in both biological duplicates were defined as IGF2BP footprints. We performed *de novo* motif identifications on eCLIP peaks using the HOMER software ^[@R42]^ with default RNA analysis parameters.

### For RNA-seq data {#S32}

All RNA-seq samples were sequenced by Illumine Hiseq 1000 with single end 51-bp read length. All reads were mapped to human genome version hg19 by hisat2 version 2.0.4 with default settings ^[@R51]^. Reads count was calculated using HTSeq ^[@R52]^, and was converted to RPKM (reads per kilobase, per million reads) using our custom Perl script. The average gene expression values of three independent studies were used for following analysis.

### For mRNA lifetime profiling {#S33}

all RNA-seq samples for mRNA lifetime were sequenced by Illumine Hiseq1000 with single end 51-bp read length. All reads were mapped to human genome version hg19 by hisat2 version 2.0.4 with default settings ^[@R51]^. Reads count was calculated using HTSeq ^[@R52]^, and was converted to RPKM (reads per kilobase, per million reads) by our custom Perl script. RPKM was converted to attomole by linear-fitting of the RNA spike-in as described by Wang et al. ^[@R10]^. The degradation rate of RNA (k) and mRNA half-life (t~1/2~) were calculated according to the aforementioned formula. The final half-life was calculated by using the average value of 1h, 3h and 6h.

### For m^6^A-seq {#S34}

Samples were sequenced by Illumine Hiseq 2000 with single end 50-bp read length. All reads were mapped to human genome version hg19 by tophat version 2.0.13 with default settings ^[@R45]^. The m^6^A level changes for shMETTL14/shNS were calculated by using exomePeak ^[@R53]^. Gene expression level changes for input and treatment were analyzed using Cuffdiff.

Integrative data analysis and statistics {#S35}
----------------------------------------

Three biological replicates of RNA-seq were conducted for shNS, shIGF2BP1, shIGF2BP2 and shIGF2BP3, respectively. The genes expression values used were the average of three replicates. The differential expression patterns of non-targets, PAR-CLIP targets and CLIP+RIP targets were compared for each IGF2BP isoform by log~2~ transformed fold change \[i.e., log~2~(shIGF2BP1/shNS), log~2~(shIGF2BP2/shNS) and log~2~(shIGF2BP3/shNS)\]. Nonparametric Mann--Whitney U-test (Wilcoxon rank-sum test, two sided, significance level = 0.05) was applied for calculating p-value ^[@R10]^. The same analysis was applied for mRNA half-life.

Gene-specific m^6^A qPCR {#S36}
------------------------

m^6^A modifications on individual genes were determined using Magna MeRIP m^6^A Kit (Millipore, Billerica, MA) following the manufacturer's instructions. Briefly, 100 μg of total RNA was sheared to about 100 nt in length by metal-ion induced fragmentation, then purified and incubated with anti-m^6^A antibody (\#202003, Synaptic Systems)- or mouse IgG (CS200621, Millipore)-conjugated beads in 500 μl 1x IP buffer supplemented with RNase inhibitors at 4 °C overnight. Methylated RNA was immunoprecipitated with beads, eluted by competition with free m^6^A, and recovered with RNeasy kit (Qiagen). One tenth of fragmented RNA was saved as input control, and further analyzed by qPCR along with MeRIPed RNA. The related enrichment of m^6^A in each sample was calculated by normalizing to ten-fold input.

Immunofluorescence and microscopy {#S37}
---------------------------------

Hela cells were grown on cover slides, fixed, and stained with indicated antibodies as previously described ^[@R54]^. Antibodies used for immunofluorescence were as follows: FLAG (F3165, 1:200, Sigma-Aldrich), HuR (\#12582, 1:200, CST), DCP1A (A303-590A-T, 1:200, Bethyl Laboratories), Alexa Fluor 488 anti-rabbit IgG (\#4412, 1:500, CST), Alexa Fluor 594 anti-mouse IgG (\#8890, 1:500, CST). Nuclei were stained by DAPI. Image acquisition was performed on a Zeiss LSM-710 confocal microscope under a 63x oil objective (Zeiss, Jena, Germany).

Polysome profiling {#S38}
------------------

We followed the procedure reported previously ^[@R14]^ with the following modifications. We started with one 15 cm dish of confluent HEK293T cells transiently overexpressing FLAG tagged IGF2BP (1, or 2, or 3) or infected with lentiviral shRNA targeting IGF2BP1. Before collection, cycloheximide (CHX) was added to the media at 100 μg/ml for 7 min. The lysis buffer was formulated as 20 mM HEPES, pH 7.6, 100 mM KCl, 5 mM MgCl~2~, 100 μg/ml CHX, 1% Triton-X-100, freshly added 1:100 protease inhibitor (Roche), 40 U/ml SUPERasin (Ambion). The sample was then fractioned into 30 fractions, 0.5 ml per fraction, and analyzed by Gradient Station (BioCamp) equipped with ECONOUV monitor (BioRad, Hercules, CA) and Gilson FC203B fraction collector (Mandel Scientific, Guelph, Canada). Sample from each fraction was subjected to western blot analysis for Flag (A5892, Sigma-Aldrich), eIF3A (\#3411, CST), eIF3B (sc-16377, Santa Cruz) and HuR (A-21277, Molecular Probes), or to qPCR analysis of *MYC* transcript.

For detection of endogenous IGF2BP proteins in ribosomal fractions, three 15 cm dishes of HepG2 cells at \~80% confluency were harvested as described above. Sample from each fraction was subjected to western blot analysis for IGF2BP1, IGF2BP2, and IGF2BP3.

Dual-Luciferase reporter assay {#S39}
------------------------------

To generate the CRD firefly luciferase reporter construct, DNA fragments of wild-type and mutant CRD were synthesized by Integrated DNA Technologies (Coralville, Iowa) and cloned into the XhoI site of pMIR-REPORT vector (Ambion, Austin, TX). HEK293T or Hela cells were seeded in triplicate in 24-well plate to allow 70% confluency in the next day. 100 ng reporter plasmids with wild-type or mutant CRD (pMIR-CRD1-wt and pMIR-CRD-mut) and 20 ng renilla luciferase control plasmids (pRL-TK) were cotransfected with or without IGF2BPs expression vectors using Lipofactamine 2000 (Invitrogen). Twenty-four hours later, firefly luciferase (Fluc) and renilla luciferase (Rluc) activities were measured with Dual-Luciferase Reporter Assay System (Promega, Madison, WI) according to the supplier's instructions. The relative luciferase activity was calculated by dividing Fluc by Rluc and normalized to individual control for each assay. For measuring *Fluc* mRNA changes, lysates left from luciferase activity measurement were lyzed with Qiazol reagent and total RNAs were extracted for qPCR analysis of *Fluc* and *Rluc* mRNA abundance. The relative luciferase mRNA was calculated as described above.

Protein co-immunoprecipitation and nLC-ESI-MS/MS {#S40}
------------------------------------------------

Cells grown in 10 cm dishes at 70--80% confluency were lysed with 500 μl NP40 buffer (150 mM NaCl, 1.5 mM MgCl~2~, 0.5% NP40, 50 mM Tris-HCl at pH8.0) and sonicated. Proteins were immunoprecipitated from 500 μg of cell lysates with FLAG or IGF2BP1 antibody and the corresponding IgG (as described above). After applying magnet, proteins associated with Protein A/G Magnetic Beads (Thermo Fisher Scientific) were washed 3 times and analyzed by Western blotting.

For mass spectrometry analysis, the protein complexes were eluted from beads by incubation with 0.2 mol/L glycine buffer (pH2.6), followed by neutralization with equal volume of 1 mol/LTris pH 8.0, and identified using nanoLC-MS/MS by the Proteomics Laboratory (University of Cincinnati, OH). Briefly, samples from immuno-enrichment with IgG and FLAG-antibodies were solubilized in Laemmli gel buffer and loaded onto separated lanes of a 4--12% MOPS mini SDS polyacrylamide gel, then electrophoresed for 15 min. The entire gel region containing the proteins was cut from the gel and subjected to in gel trypsin digestion and subsequent recovery of peptides as described previously ^[@R55]^. The recovered peptides were introduced into an Eksigent (Dublin, CA) nanoLC.ultra nanoflow system attached to a TripleTOF 5600 plus (Sciex, Toronto, Canada) for nLC-ESI-MS/MS analyses. Data were recorded using Analyst®-TF (v.1.7) software. Searches from the nLC-MS/MS were accomplished using ProteinPilot software (version 5.0, revision 4769) that utilizes Paragon algorithm (ver 5.0.0.0, 4769) against the complete database of Homo sapiens protein (20342 proteins) downloaded from [ftp.uniprot.org](ftp.uniprot.org) on 1/21/16.

Lentiviral shRNA infection {#S41}
--------------------------

Lentiviruses were produced in HEK293T cells by co-transfecting individual shRNA construct with packing vectors (pMD2.G, pMDLg/pRRE and pRSV-Rev) into HEK293T cells in 60 mm cell culture dish using X-tremeGENE HP DNA Transfection Reagent (Roche Diagnostics, Grenzach-Wyhlen, Germany). The lentivirus particles were harvested at 48 and 72 hours after transfection and directly added into target cells with 4 μg/ml polybrene. After two rounds of infection, cells were selected for at least two passages by adding 1 μg/ml puromycin into growth medium.

Cell proliferation, migration and invasion assays {#S42}
-------------------------------------------------

Hela and HepG2 cells were seeded in 96-well plates at 1000 cells/well. Cell proliferation was evaluated by MTT Assay (Promega).

For colony formation assay, 2000 Hela cells or 10000 HepG2 cells were seeded in 6-well plates and stained with crystal violet 7--10 days later. Colonies were counted in three random fields under a 5x microscope.

For cell migration and invasion transwell assays, 25000 HepG2 cells or 50000 Hela cells in 500 μl starvation media were plated on the top chambers of Transwell Clear Polyester Membrane Inserts (for migration assay, Corning Costar, Vienna, Austria) and BioCoat Matrigel Invasion Chambers (for invasion assay, Corning Costar), while culture media with 20% FBS was applied on the bottom. After 48 to 72 hours, migrated or invaded cells were stained with crystal violet and counted under a 20x microscope.

For the wound healing assay, Hela and HepG2 cells were seeded in 24 well plates and allowed to grow to confluent monolayer in 24 hours. Cells were then scratched and allowed to continue to culture in complete culture media to allow for migration for 24--72 hours. Images were taken at indicated time under microscope. The scratched areas were quantified using Adobe Photoshop and used to calculate migration rate.

RNA isolation and quantitative RT-PCR {#S43}
-------------------------------------

Total RNA was isolated from cultured cells using miRNeasy Kit (Qiagen, Valencia, CA) or Trizol reagent (Invitrogen). First strand cDNA was synthesized by reverse transcription of 500 ng RNA using QuantiTect Reverse Transcription Kit (Qiagen). Quantitative PCR (qPCR) was carried out using QuantiTect SYBR Green PCR Kit (Qiagen) and mRNA expression was normalized to reference genes, GAPDH and TATA-binding protein (TBP). The primers used in all qPCR assays were listed in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}.

CRISPR-CSP9 KO {#S44}
--------------

Human HepG2 cells were transiently transfected with a modified pSpCas9(BB)-2A-GFP plasmids (Addgene, \#48138) containing IGF2BP1, IGF2BP2, or IGF2BP3 sgRNAs with optimized scaffold ^[@R56]^ and a high fidelity eSpCas9(1.1) ^[@R57]^ using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. Single cells were isolated 48 hours after transfection by FACS (BD FACS Aria III) into 96-well plates. Only cells with high GFP (top 4%) were selected. Independent clones were allowed to grow for three weeks. Knockout efficiency was tested by Western blotting with specific antibodies. The sgRNA sequences used are listed below: IGF2BP1, TATTCCACCCCAGCTCCGAT; IGF2BP2, GAGAAGTGCCCCCAGGGGCG; IGF2BP3, TGGCACCGACTGATAGAGCT.

Statistics and reproducibility {#S45}
------------------------------

Statistical comparisons were performed by using *t*-tests (two tailed) or Wilcoxon and Mann-Whitney test as indicated in the figure legends. Data are presented as mean ± s.d.. *P* \< 0.05 was considered significant. The number of biological (non-technical) replicates for each experiment is indicated in the figure legends. Three independent sets of RNA samples were used for RNA-seq, two independent sets of RNA samples were used for mRNA stability profiling, and two set of RNA samples was used for m^6^A-seq. All Western blot, dot blot, and immunofluorescence images are representative of three independent experiments. No statistical method was used to predetermine sample size.

Code availability {#S46}
-----------------

The custom Perl and R scripts used in this study are available on request to the corresponding authors.

Data availability {#S47}
-----------------

All sequencing data that support the findings of this study have been deposited in NCBI's Gene Expression Omnibus (GEO) under accession number GSE90639 (for RIP-seq), GES90642 (for m^6^A-seq), and GSE90684 (for RNA-seq). Data for LC/MS/MS of IGF2BP2 coimmunoprecipitation have been deposited to Figshare (<http://dx.doi.org/10.6084/m9.figshare.5693410>). Previously published ENCODE PAR-CLIP and eCLIP data that were re-analyzed here are available under accession code: GSE21918 (for PAR-CLIP of IGF2BPs), GSE92021 (for IGF2BP1 eCLIP in HepG2),GSE92220 (for IGF2BP3 eCLIP in HepG2) and GSE78509 (for IGF2BPs eCLIP in hESCs).The human cancer data were derived from the TCGA Research Network (<http://cancergenome.nih.gov/>). The data-set derived from this resource that supports the findings of this study is available in cBioPortal for Cancer Genomics (<http://www.cbioportal.org/>, using TCGA pan-cancer studies).

Source data for [Figures 1c, 1k](#F1){ref-type="fig"}, [2c, 2f](#F2){ref-type="fig"}, [3d, 3e](#F3){ref-type="fig"}, [4b, 4c, 4d, 4f, 4g, 4h, 4i, 4j](#F4){ref-type="fig"}, [5d, 5e, 5f](#F5){ref-type="fig"}, [6b, 6c, 6d](#F6){ref-type="fig"}, [7b, 7c, 7d](#F7){ref-type="fig"} and [Supplementary Figures 2e, 3d, 3e, 3f, 4c, 5a, 5d, 6d, 6f, 6g, 6h, 6i, 6j](#SD2){ref-type="supplementary-material"} are provided as [Supplementary Table 3](#SD1){ref-type="supplementary-material"}. All other data supporting the findings of this study are available from the corresponding authors on reasonable request.
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![Selective binding of IGF2BPs to m^6^A-modified RNAs\
(**a**) Identification of m^6^A specific binding proteins by RNA affinity chromatography using ssRNA probes with methylated (red) or unmethylated (green) adenosine. Silver staining (lower left) and Western blotting (lower right) showed selective pulldown of \~68kDa IGF2BP proteins from HEK293T nuclear extract. Western blot images were representative of 3 independent experiments. (**b**) Enrichment of m^6^A consensus sequence "GGAC" in the binding sites of RBPs. The three IGF2BP paralogues were shown in red, while the YTH domain proteins were shown in orange. (**c**) Quantification of m^6^A/A and m^6^A/AGCU ratios by LC-MS/MS in RNAs bound by ectopically expressed IGF2BP1 (chicken ZBP1), IGF2BP2 (human), or IGF2BP3 (human). Values are mean of n =2 independent experiments and individual data points are showed. (**d**) Overlap of IGF2BP target genes identified by RIP-seq and published PAR-CLIP in HEK293T cells. RIP-seq was performed once. *P* value was calculated by Fisher's test. (**e**) Venn diagram showing the numbers of shared high-confidence targets (*i.e.*, CLIP+RIP targets) amongst IGF2BP paralogues. *P* value was calculated by Fisher's test. (**f**) Top consensus sequences of IGF2BP binding sites and the m^6^A motif detected by HOMER Motif analysis with PAR-CLIP data. (**g**) Pie charts showing numbers and percentages of IGF2BP high-confidence target genes that contain m^6^A peaks. The m^6^A-seq data was reported in Ref. ^[@R3]^. (**h**) Metagene profiles of enrichment of IGF2BP binding sites and m^6^A modifications across mRNA transcriptome. (**i**) Percentages of various RNA species bound by IGF2BPs. (**j**) The distribution (upper) and enrichment (lower) of IGF2BPs binding peaks within different gene reions. The enrichment was determined by the proportion of IGF2BPs binding peaks normalized by the length of the region. Analyses in **i** and **j** were performed twice with similar results. (**k**) *In vivo* binding of Flag-IGF2BP2 to representative target genes in *METTL14* knockdown or control HEK293T cells. Values are mean±s.d. of n =3 independent experiments. \*, *P*\<0.05; \*\*, *P* \<0.01; \*\*\*, *P* \<0.001; two-tailed Student's *t*-test. Unprocessed scans of western blot analysis are available in [Supplementary Figure 8](#SD2){ref-type="supplementary-material"}. Source data of **c** and **k** are in [Supplementary Table 3](#SD1){ref-type="supplementary-material"}.](nihms937118f1){#F1}

![IGF2BPs regulate transcriptome-wide mRNA levels\
(**a**) Volcano plots displaying enrichment of dysregulated target genes in *IGF2BP* knockdown (shIGF2BP) vs. control (shNS) HepG2 cells. The numbers of significantly downregulated (log~2~FC\<−1, *P*\<0.05, two-tailed Student's *t*-test) or upregulated genes (log~2~FC\>1, *P*\<0.05, two-tailed Student's *t*-test) in the CLIP target group and CLIP+RIP target group are shown. FC, fold change. (**b**) Cumulative frequency of mRNA log2-fold change in non-target, CLIP target and CLIP+RIP target genes upon *IGF2BP* silencing. *P* values were calculated using two-sided Wilcoxon and Mann-Whitney test. (**c**) Relative changes in *FSCN1*, *TK1*, *MARCKSL1,* and *MYC* mRNA levels upon *IGF2BP* silencing. Results from 2 shRNAs for each *IGF2BP* are shown. Values are mean±s.d. of n = 3 independent experiments. Two-tailed Student's *t*-tests were used (\*\*, *P* \<0.01; \*\*\*, *P* \<0.001). (**d**) Distribution of genes with a significant change in both m^6^A level and gene expression level in *METTL14* knockdown HepG2 cells compared to control cells. (**e**) Cumulative frequency of mRNA log~2~-fold change showing global reduction of IGF2BPs high-confidence target genes in shMETTL14 vs. shNS cells. *P* values were calculated using two-sided Wilcoxon and Mann-Whitney test. Exponential regression was used in **d** and **e**. Gene expression in **a**, **b** were analyzed for three times, while **e** were analyzed twice. (**f**) Relative changes in *FSCN1*, *TK1*, *MARCKSL1*, and *MYC* mRNA levels upon *METTL3* or *METL14* silencing. Values are mean±s.d. of n =3 independent experiments. Two-tailed Student's *t*-tests were used (\*\*, *P* \<0.01; \*\*\*, *P* \<0.001). Source data of **c** and **f** are in [Supplementary Table 3](#SD1){ref-type="supplementary-material"}.](nihms937118f2){#F2}

![Knockdown of IGF2BPs decreases mRNA stability\
(**a**) Cumulative distribution of mRNA half-lives of non-target or IGF2BP high-confidence target genes in HepG2 (left) and Hela (right) cells. (**b**) Distribution of mRNA half-lives in IGF2BP3 high-confidence targets in HepG2 cells with shIGF2BP3 or shNS. (**c**) Cumulative distribution of mRNA half-life of IGF2BP3 high-confidence targets in shIGF2BP3 or shNS HepG2 cells. mRNA half-life analyses in a, b and c were repeated twice. (**d** and **e**) Reducing *MYC* mRNA half-life by silencing *IGF2BPs* (**d**) or m^6^A writers (**e**) in HepG2 cells. Values are mean±s.d. of n =3 independent experiments. (**f**) Co-Immunoprecipitation and Western blotting showing the binding of mRNA stabilizers with FLAG-tagged IGF2BPs in HEK293T cells, representative of 3 independent experiments. (**g** and **h**) Co-localization of IGF2BP proteins with HuR (**g**) or DCP1A (**h**) in Hela cells. Arrows indicate co-localization in cytoplasmic granules. Scale bar=10μm. Images were representative of 3 independent experiments. *P* values were calculated using two-sided Wilcoxon and Mann-Whitney test in **a**, **b**, **c**. Unprocessed scans of western blot analysis are available in [Supplementary Figure 8](#SD2){ref-type="supplementary-material"}. Source data of **d** and **e** are in [Supplementary Table 3](#SD2){ref-type="supplementary-material"}.](nihms937118f3){#F3}

![IGF2BPs regulate *MYC* expression through binding to methylated CRD\
(**a**) Distribution of m^6^A peaks across *MYC* mRNA transcript. The coding region instability determinant (CRD) region is highlighted in yellow. m^6^A-seq was repeated twice while RIP-seq was performed once.(**b**) RIP-qPCR showing the association of *MYC* CRD with FLAG-tagged IGF2BPs in HEK293T cells. (**c**) Enrichment of m^6^A modification in *MYC* CRD as detected by gene specific m^6^A qPCR assay. (**d**) RIP-qPCR showing the binding of METTL3 and METTL14 to the *MYC* CRD. (**e**) RNA pulldown of endogenous IGF2BP proteins from HEK293T nuclear extract using synthetic CRD RNA fragments, CRD1 and CRD2, with (m^6^A) or without (A) m^6^A modifications. Images are representative of 3 independent experiments. (**f**) Relative firefly luciferase (Fluc) activity (i.e., protein level; left) and *Fluc* mRNA level (right) of wild-type (CRD-wt) or mutated (CRD-mut) CRD reporters in HEK293T cells with ectopically expressed IGF2BP1, IGF2BP2, or IGF2BP3. (**g**) RIP-qPCR detecting the *in vivo* binding of Flag-IGF2BPs to the transcripts of CRD-wt or CRD-mut luciferase reporter in HEK293T cells. (**h** and **i**) Relative luciferase activity of CRD-wt or CRD-mut in Hela cells with or without stable knockdown of *IGF2BPs* (h) or *METTL14* (i). (**j**) Relative luciferase activity of CRD-wt or CRD-mut in *METTL14* stable knockdown or control Hela cells with ectopic expression of *IGF2BPs*. For all luciferase assays, the Fluc/Rluc ratio (representing luciferase activity) of CRD-wt with empty vector or shNS was used for normalization. Values are mean±s.d. of n =3 independent experiments, and two-tailed Student's *t*-tests were used in **b**, **c**, **d**, **f**, **g**, **h**, **i**, **j**. (\*\*, *P* \<0.01; \*\*\*, *P* \<0.001). Unprocessed scans of western blot analysis are available in [Supplementary Figure 8](#SD2){ref-type="supplementary-material"}. Source data of **b**, **c**, **d**, **f**, **g**, **h**, **i**, **j** are in [Supplementary Table 3](#SD1){ref-type="supplementary-material"}.](nihms937118f4){#F4}

![The KH domains of IGF2BPs are critical for m^6^A recognition and binding\
(**a**) Schematic structures showing RNA binding domains within IGF2BP proteins and a summary of IGF2BP variants used in this study. Blue boxes are RRM domains, red boxes are wild-type KH domains with GxxG core, and grey boxes are inactive KH domain with GxxG to GEEG conversions. (**b**) RNA pulldown followed by Western blotting showed *in vitro* binding of ssRNA baits with wild-type (wt) or KH domain-mutated IGF2BP variants, representative of 3 independent experiments. (**c**) *In vitro* binding of CRD1 RNA probes with wild-type or KH3-4 mutated IGF2BPs, representative of 3 independent experiments. (**d**) The association of wild-type and KH3-4 mutated IGF2BPs with *MYC* CRD in HEK293T cells as assessed by RIP-qPCR. (**e**) Relative luciferase activity of CRD reporters in HEK293T cells with forced expression of wild-type or mutated IGF2BP2 variants. (**f**) Changes in *MYC* mRNA levels in Hela cells with empty vector or forced expression of wild-type or KH3-4 mutated IGF2BPs one hour post-heat shock (HS). Values are mean±s.d. of n =3 independent experiments, and two-tailed Student's *t*-tests were used in **d**, **e**, **f** (\*, *P* \<0.05; \*\*, *P* \<0.01; \*\*\*, *P* \<0.001). Unprocessed scans of western blot analysis are available in [Supplementary Figure 8](#SD2){ref-type="supplementary-material"}. Source data of **d**, **e**, **f** are in [Supplementary Table 3](#SD1){ref-type="supplementary-material"}.](nihms937118f5){#F5}

![The oncogenic functions of IGF2BPs in human cancer cells\
(**a**) Western blot showing depletion of MYC protein in IGF2BPs-silenced Hela and HepG2 cells, representative of 3 independent experiments. (**b**) Inhibition of cell proliferation in *IGF2BP*-silenced cells compared to control cells as determined by MTT assays. Values are mean±s.d. of n =3 independent experiments. Two-tailed Student's *t*-tests were used (\*\*\*, *P* \<0.001). (**c**) Effect of *IGF2BP* silencing on colony formation ability. Representative images of crystal violet staining of cells in 6-well plate are shown on top of the histograms. Colonies were counted from 3 replicate wells and 2 independent experiments were performed. The colony number of each experiment represents the total count of 3 replicate wells. (**d**) Repression of migration and invasion by shRNAs against *IGF2BPs*. Numbers of migrated or invaded cells were counted from 3 replicate wells and 2 independent experiments were performed. The numbers in the control (shNS) groups were set as 1. Unprocessed scans of western blot analysis are available in [Supplementary Figure 8](#SD2){ref-type="supplementary-material"}. Source data of **b**, **c**, **d** are in [Supplementary Table 3](#SD1){ref-type="supplementary-material"}.](nihms937118f6){#F6}

![IGF2BPs are oncogenic m^6^A readers\
(**a**) CRISPR-Cas9 mediated knockout (KO) of *IGF2BPs* and the subsequent depletion of MYC in HepG2 cells as detected by Western blotting. Images were representative of 3 independent experiments. (**b**) Effect of wild-type or KH3-4 mutated IGF2BPs on restoring cell proliferation in *IGF2BP*-KO cells. Data shown represent mean value of viable cell numbers of 2 independent experiments. (**c**) Colony formation assay using wild-type (WT) or *IGF2BP* KO (sgIGF2BP) HepG2 cells. Representative images of crystal violet staining of cells were shown on top of the histograms of colony numbers. Colonies were counted from 3 replicate wells of and 2 independent experiments were performed. The colony number of each experiment represents the average count of 3 replicate wells. (**d**) MTT assays displaying the effect of MYC on restoring cell proliferation in IGF2BP-KO cells. Values are mean±s.d. of n =3 independent experiments. Two-tailed student *t*-test were used (\*\*, P \<0.01; \*\*\*, P \<0.001). (**e**) Working model of IGF2BP-mediated regulation of m6A modified mRNAs. mRNAs were methylated *de novo* by the methyltransferase complex composed of METTL3, METTL14 and a regulatory subunit WTAP. The naïve mRNA with m^6^A modifications were preferentially recognized by IGF2BP proteins. By recruiting mRNA stabilizers, such as HuR and MATR3, IGF2BPs protect target mRNAs from degradation in the P-body while facilitating translation after being exported to cytoplasm. Under stress conditions such as heat shock, IGF2BP-containing mRNPs are translocated to stress granules for the storage of their mRNA targets. Unprocessed scans of western blot analysis are available in [Supplementary Figure 8](#SD2){ref-type="supplementary-material"}. Source data of **b**, **c**, **d** are in [Supplementary Table 3](#SD1){ref-type="supplementary-material"}.](nihms937118f7){#F7}
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